Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.20B
EPS-6.8600
P/E Ratio-1.65
Earnings Date08/10/2026

bhvn

Other Current Assets

Last Annual Value

49.19M

3-Year CAGR

-3%

5-Year CAGR

447%

10-Year CAGR

25%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Other Current Assets

BHVN · NYSE
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
49.19M
59.5%32.5%N/A 
68.36M
11.2%N/A44.0%
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
7.29M
13.5%N/AN/A
11.01M
50.7%87.1%N/A
5.54M
100.6%N/AN/A
7.98M
39.4%N/AN/A
9.55M
18.2%N/AN/A
14.08M
37.1%N/AN/A
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $11.35